Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSI-78 vs Ofloxacin in Infected Diabetic Ulcers
NCT00563394Phase 3Completed
- Sponsor
- Abeona Therapeutics Inc.
- Start
- Aug 1994
- Primary completion
- Jul 1996
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pexiganan in diabetic foot infection (DFI) (2 arms), sponsored by Abeona Therapeutics Inc. Primary endpoint: Reduction in clinical signs and symptoms of the infection at 10 days. Started Aug 1994; status: completed.
02
Drugs
pexiganan
03
Conditions
diabetic foot infection (DFI)
Beyond the preview
Go deeper on NCT00563394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00563394.